KPV is not FDA approved and is not on the list of substances US pharmacies may compound. A committee backed it 8 to 6 in July 2026, against FDA staff. The HHS draft policy of 30 October 2026 covers KPV acetate only as a topical or oral product. The FDA found no study of KPV in humans.

The short version. KPV is not FDA approved and is not on the 503A Bulks List. A committee voted for listing it on 23 July 2026, against FDA staff. A draft HHS policy of 30 October 2026 covers KPV acetate only as a topical or oral product. No study of KPV in humans exists in the FDA record.
KPV is a tripeptide made of lysine, proline and valine, the last three amino acids of alpha-melanocyte-stimulating hormone, or alpha-MSH, a hormone made in the pituitary gland. The FDA briefing document prepared for the July 2026 Pharmacy Compounding Advisory Committee describes it as a fragment the body produces naturally, synthesised commercially by solid-phase peptide synthesis. Alpha-MSH acts through melanocortin receptors, but the FDA notes that several lab studies found KPV did not bind those receptors or trigger their signalling, and that its molecular target remains unknown. Researchers have proposed that KPV dampens inflammation by blocking NF-kappaB signalling and that intestinal cells take it up through a transporter called PepT1, but those are hypotheses from cell and animal work.
KPV has the same naming problem the FDA found across the July review. The single nomination, from Wells Pharmacy Network, did not make clear whether it meant KPV free base or KPV acetate, which are different active ingredients: its certificate of analysis named the acetate while its registry number and formula matched the free base, and both forms share one CAS number in most public references. The agency evaluated both forms on its own initiative after the nomination was withdrawn. Online, the FDA found KPV promoted for inflammatory bowel disease, Crohn's disease, psoriasis, mast cell activation, COVID-19 recovery, Lyme disease and mould toxicity, sold as injections, capsules, creams and nasal sprays, and bundled with BPC-157 and TB-500 as a regenerative combination.

In plain EnglishKPV is a tiny piece of a natural hormone. A lab-made version is sold for inflammation, gut and skin problems. In the US it is not an approved drug, and the FDA found no published study of giving it to people.
KPV's legal position rests on four dated facts. First, the FDA briefing states that neither KPV free base nor KPV acetate is a component of an FDA approved drug, and neither has a USP or National Formulary monograph. Second, KPV is not on the 503A Bulks List, the list of substances state-licensed pharmacies may use to compound, and no proposed or final rule has added it. Third, law firm McDermott Will & Schulte reported that HHS confirmed KPV's removal from Category 2 on 15 April 2026, after the nomination was withdrawn, and stressed that leaving Category 2 is not the same as entering Category 1. Fourth, on 30 October 2026 HHS published in the Federal Register a draft enforcement discretion policy that names KPV among six peptides, which is the newest and most misread of the four.
| Question | What the record says | Source |
|---|---|---|
| FDA approved product? | None. Not a component of any approved drug | FDA briefing, PCAC July 2026 |
| On the 503A Bulks List? | No | No proposed or final rule |
| FDA staff view | Balance of criteria weighs against listing | FDA briefing memo, 12 May 2026 |
| Advisory committee | In favour, 8 to 6 with 1 abstention, both forms | McDermott, 27 Jul 2026; FDA Law Blog, 24 Jul 2026 |
| HHS draft policy | No intended enforcement for KPV acetate, topical and oral forms only | FR Doc. 2026-22192, 30 Oct 2026; BakerHostetler and FDA Law Blog, 28 Oct 2026 |
| Injectable KPV under that policy? | Not covered | BakerHostetler; FDA Law Blog, 28 Oct 2026 |
The HHS notice, FR Doc. 2026-22192, says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a peptide listed in its Appendix A, while FDA develops the 503A list through rulemaking. The notice itself calls the policy a draft, says it is not binding on HHS or the public, opened comments for two weeks, and says HHS may revisit it if a safety signal or quality problem appears. The appendix sits on hhs.gov, which refused our requests on 3 November 2026, so the route detail here is as reported by BakerHostetler and the FDA Law Blog on 28 October 2026: KPV acetate for topical and oral dosage forms, with oral products needing documented bioavailability. Foley & Lardner adds that each product may contain one active ingredient only.

In plain EnglishA committee said yes by two votes, and HHS has said in a draft that it will not go after pharmacies making KPV creams or oral forms. KPV injections, and KPV mixed with other peptides, are outside that draft. None of this is an approval.
KPV is promoted online as an injection. The HHS draft covers it only as a cream or an oral form, and the FDA found no study in which it was given to a human by any route.
The committee vote is the fact most often misreported. On 23 July 2026 the committee voted separately on KPV free base and KPV acetate, and McDermott Will & Schulte and the FDA Law Blog reported the same result for both: 8 in favour, 6 against and 1 abstention, for wound healing and inflammatory conditions. The FDA Law Blog noted that the votes ran flatly against the recommendation of the FDA's own scientific review team. The Ozemback peptide legal status tracker carries KPV in the "recommended, not law" group with BPC-157, TB-500, MOTS-c, Epitalon and Semax, with the date of each fact, and will change the row on the day the FDA proposes or finalises a rule. For how the committee overrode its staff, see our analysis of the vote, or try the approved, recommended or neither quiz.
The FDA's conclusion: a lack of evidence to evaluate effectiveness for wound healing or inflammatory conditions, no information on KPV given to humans, and FDA approved therapies already available for both.

The nomination proposed KPV as a topical cream or gel for wound healing and inflammatory skin conditions such as psoriasis and eczema. It cited nine references in support, and the FDA found that none studied KPV in humans: eight looked at alpha-MSH derivatives in animals and one measured how KPV moves through human cadaver skin. The agency's own literature search, across PubMed, Embase and ClinicalTrials.gov, found no clinical study either. What the record does contain is animal and cell work: less intestinal inflammation in animal models (Dalmasso and colleagues, 2008), faster healing in rodent models of skin and corneal wounds, and lower inflammatory signalling in cultured human gut and immune cells. The FDA notes that researchers themselves have called for clinical studies before KPV could be judged as a wound treatment.
The most practical finding in the record concerns skin. In Pawar and colleagues in 2017, KPV applied to human cadaver skin in the lab did not permeate well through the outer layer, the stratum corneum. The FDA reads that two ways: poor penetration could limit systemic side effects of a cream, but it could also stop the peptide from reaching the layers where it would need to act. Iontophoresis and microneedle abrasion pushed more KPV through in that study, and the FDA says studies are still needed to find out whether those methods also raise absorption into the blood. The agency also found the free base dissolves in water at only 0.7 mg per millilitre, and without a stated vehicle it could not judge how a cream would perform.
In plain EnglishMice, rats and cells responded in interesting ways. No person has been studied. In the one test on human skin, KPV barely got through. The FDA concluded there is nothing yet to show it works for wounds, skin or gut inflammation in people.
The FDA's safety conclusion is that potential risks of KPV in humans are unknown. Its FAERS search, through 3 December 2025, returned no reports, and a search of the Human Foods Complaint System from January 2004 to 3 December 2025 found no cases, but compounders under section 503A generally do not report adverse events, so an empty database proves little. The agency found no acute, repeat-dose, genetic, reproductive or carcinogenicity toxicity studies of either form, and no pharmacokinetic study in any species. It flagged immunogenicity and aggregation, noting that peptides as short as two amino acids can aggregate. On quality, the only certificate of analysis supplied showed no aggregate or microbiological testing, which topical products require.
There is no FDA approved dose of KPV, because there is no FDA approved product.
Every KPV dose figure you will find in the US comes from somewhere other than a US label. The nomination proposed a topical cream or gel at a single strength without saying what base it would be made in, and the animal studies dosed by body weight or by local application in rodents, which does not translate into a human dose. The FDA found no pharmacokinetic study in people or animals, so the record says nothing about how the body absorbs or clears KPV by any route, and outsourcing facilities reported compounding no KPV product between January 2017 and June 2025. The HHS draft policy sets routes, not doses. We report this because it is the record, and we do not publish a recommended dose, cycle or protocol for KPV or any other compound.

Check whether the page treats animal gut and wound results as if they were human results; every effect in the record comes from rodents or cells. Check whether it says KPV is "now legal" after the HHS announcement without saying which form and route; the draft covers KPV acetate as a cream or oral product, not injections or blends. Check whether it reports the July 2026 vote as a recommendation or as a change in the law; only the first is accurate. Check who pays the author: nearly every site ranking for KPV benefits or dosage sells it, sells a consultation or links to a seller. This page carries a date at the top, 3 November 2026, so you can tell when it stops being current. Related files: BPC-157 and TB-500, voted on the same day.
KPV is not an FDA approved drug and is not on the 503A Bulks List. An FDA advisory committee voted 8 to 6, with one abstention, in favour of listing it on 23 July 2026, a recommendation with no rule behind it. On 30 October 2026 HHS published a draft, non-binding policy saying it does not intend to act against pharmacies compounding KPV acetate in topical and oral forms. Whether a specific seller is acting lawfully is a question for a lawyer.
Not under the HHS draft policy. BakerHostetler and the FDA Law Blog both report that its appendix lists KPV acetate for topical and oral dosage forms only, while injectable forms are listed for TB-500, MOTS-c and Epitalon. The policy also requires a single active ingredient, so blends such as KPV with BPC-157 fall outside it.
No. The FDA briefing states that neither KPV free base nor KPV acetate is a component of an FDA approved drug, and neither has a USP or National Formulary monograph. The FDA also found no monograph in the European or Japanese pharmacopoeias and no authorised product listed by the European Medicines Agency.
Not in any human study, because there is none. The results come from rodents and cells, such as animal models of gut inflammation and wounds. The FDA concluded there is a lack of evidence to evaluate KPV for wound healing or inflammatory conditions, and noted that FDA approved treatments exist for both.
There is no FDA approved dose, because there is no FDA approved product. Figures on pages that rank for this query come from sellers and clinics, not from a US label, and the FDA found no pharmacokinetic study in any species. We do not publish a dose, cycle or protocol for this or any compound.
Unknown, which is not the same as none. The FDA found no FAERS reports through 3 December 2025 and no human exposure data of any kind. It flagged immune reactions and aggregation as concerns for any peptide. Compounders generally do not report adverse events, so an empty database proves little.
No. KPV is the last three amino acids of alpha-MSH. The FDA notes that KPV does not appear to work through the melanocortin receptors alpha-MSH uses, and its molecular target is unknown. The peptide legal status tracker carries its legal position.
Whatever you decide, your own numbers are the one part of this that is not contested. A baseline panel costs less than a month of most things sold in this category and it is yours to keep.
Ozemback is not a provider and takes no part in any clinical decision. The link above is an affiliate link: if you buy a panel through it we receive a commission at no additional cost to you. We are paid for the referral, never for the result, and it does not change what we publish.